The development of liquid biopsies has fostered a means of obtaining the information needed to aid in a faster, simpler diagnosis and possibly faster prognosis.
In 2016, the Food and Drug Administration (FDA) approved the first liquid biopsy test. Originally intended for the blood plasma screening of patients with metastatic non-small cell lung cancer (NSCLC) with possible mutations in the epidermal growth factor receptor (EGFR) gene, the technique has since branched to many other lung cancer situations.
Today, liquid biopsies have further demonstrated increasingly therapeutic potential in detecting ctDNA and CTCs within body fluids. The procedure provides clinicians and patients with a minimally invasive screening which can provide early diagnosis results, identification of molecular markers, and insight into the tumor over time.